News Highlights At Biotechnology Industry: Gilead Sciences Inc. (NASDAQ:GILD), MannKind Corp. (NASDAQ:MNKD), Endocyte, Inc. (NASDAQ:ECYT), Nektar Therapeutics (NASDAQ:NKTR)

September 29, 2014 1:24 PM

28 0

Gilead Sciences Inc. (NASDAQ:GILD) [Trend Analysis] reported that it won the backing of the European Medicines Agency for a hepatitis C treatment with the intention of pairs its Sovaldi with another drug, ledipasvir, to deliver a one-two punch to the virus. Gilead Sciences Inc. (NASDAQ:GILD) stock closed at $108.38 in last session with the total traded volume of 10.82 Million. As taking short look on the firm profit margin was recorded 42.80%, and operating margin was recorded 56.20%. The Financial Institutional ownership of the firm was 92.80% while by insiders was 0.40%.

MannKind Corp. (NASDAQ:MNKD) [Trend Analysis] has been in search of a appropriate partner ever since the FDA cleared Afrezza inhalation powder for the improvement of glycemic control in adults suffering from diabetes mellitus in Jun 2014. In Aug 2014, MannKind Corp. (NASDAQ:MNKD) moved down -1.13% t...

Read more

To category page